The aim of the present study was to delineate the mechanism(s) responsible for the increased secretion of VLDL (very-low-density lipoprotein) particles in patients with FCH (familial combined hyperlipidaemia). In 194 young adults (< 25 years of age) recruited from families with FCH, we investigated how plasma lipids, (apo)lipoproteins and BMI (body mass index) varied with age. Furthermore, we performed a 5-year follow-up study of clinical and biochemical characteristics of a subset of this population (n = 85) stratified by apoB (apolipoprotein B) levels (below or above the 75th percentile adjusted for age and gender). Plasma apoB concentration (r = 0.45, P < 0.0001), triacylglycerol (triglyceride) concentration (r = 0.45, P < 0.0001), LDL (low-density lipoprotein) subfraction profile (r = − 0.46, P < 0.0001) and BMI (r = 0.51, P < 0.0001) were significantly associated with age. Plasma apoB concentration in the hyperapoB group was already elevated at a young age, whereas other characteristics of FCH, as observed in adults, including triacylglycerol levels > 1.5 mmol/l and/or small-dense LDL, were observed only sporadically. After the 5-year follow-up, BMI increased in both groups, and this increase was associated with changes in apoB (r = 0.27, P < 0.05), triacylglycerol (r = 0.30, P < 0.01), VLDL cholesterol (r = 0.22, P < 0.05), VLDL triacylglycerol (r = 0.25, P < 0.05) and high-density lipoprotein cholesterol (r = − 0.27, P < 0.05).
INTRODUCTION
FCH (familial combined hyperlipidaemia) is the most common of the familial atherogenic dyslipoproteinaemias with a prevalence of up to 5.7 % in the general population [1] . The lipid profile of FCH is complex, and affected subjects may present with hypercholesterolaemia, hypertriglyceridaemia or mixed hyperlipidaemia; worse still, the lipid profile may vary over time in the same subject. Thus, based on lipids, the hallmarks of FCH are variability among subjects and within subjects. Among all of this variability, increased concentrations of apoB (apolipoprotein B) and sdLDL [small-dense LDL (lowdensity lipoprotein)] stand out as the two most consistent abnormalities in subjects with FCH [2] [3] [4] [5] [6] . These abnormalities might result from a decreased fractional catabolic rate of apoB-containing particles [7] , but the majority of studies show that the increased concentrations of apoB and the presence of sdLDL are rather a consequence of increased secretion of VLDL (very-low-density lipoprotein) particles [8] [9] [10] [11] [12] [13] . However, the specific abnormalities responsible for an increased secretion of VLDL remain unknown. One hypothesis is that increased hepatic NEFA (non-esterified fatty acid; 'free fatty acid') flux due to increased transmembrane adipose tissue NEFA flux is responsible [2] . As upper-body adipose tissue mass increases, so does transmembrane adipocyte NEFA flux and, therefore, this model predicts age-related expression of the disorder. A second model posits that a primary disorder in the regulation of hepatic sterol balance could be responsible for increased VLDL secretion in which case expression should not be age-dependent [14, 15] . The first model is more consistent with a phenotype of hypertriglyceridaemia/hyperapoB with increased secretion of relatively TG [triacylglycerol (triglyceride)]-rich VLDL, the second with a phenotype of normotriglyceridaemia/hyperapoB and increased secretion of relatively cholesterol-rich VLDL. However, neither model alone would explain the heterogeneity of the lipid phenotypes in FCH.
The aim of the present study was to determine whether we could find evidence for one or other of these models, one reflecting the fundamental genetically determined metabolic abnormality and the other reflecting the impact of age-related factors, such as expansion of adipose tissue mass. Therefore we explored the phenotype of FCH in young adults recruited from families affected by FCH. Moreover, the effect of time and subsequent increases in weight on the phenotype in these subjects was determined in a 5-year follow-up study.
MATERIALS AND METHODS

Study population
The study population consisted of kindreds of families with known FCH recruited in 1994, 1999 or 2004 and followed up in 1999 and/or 2004 [6, 16, 17] . All FCH kindreds were recruited by family studies of probands attending the outpatient clinic of the University Medical Centre Nijmegen, Nijmegen, The Netherlands. Families were included when, besides a proband presenting with combined hyperlipidaemia, at least one first-degree relative presented with hypertriglyceridaemia, hypercholesterolaemia or a combined hyperlipidaemia. Furthermore, at least the proband or one of the first-degree relatives had to have CVD (cardiovascular disease) before the age of 60 years. Families were excluded when a secondary cause of hyperlipidaemia was diagnosed in the proband (i.e., diabetes mellitus, hypothyroidism and hepatic or renal impairment). None of the probands was homozygous for the apoE2 (apolipoprotein E2) allele, and none of the probands or first-degree relatives had tendon xanthomas. All subjects in this study were Caucasian.
On every visit, all subjects filled in a questionnaire about their previous medical history, medication use, and smoking and drinking habits. CVD was defined by stroke, transient ischaemic attack, myocardial infarction, angina pectoris and/or peripheral vascular disease. On all occasions, weight and height were measured and BMI (body mass index) was calculated as body weight (in kg) divided by the square of height (in m). Furthermore, venous blood was drawn by venipuncture after an overnight fast and after withdrawal of lipid-lowering medication (if used) for 4 weeks. A total of 194 subjects < 25 years of age were recruited from 29 different families (6.6 subjects/family) with an average family size of 30 subjects/family. These patients were seen on one or more visits and, for this group, associations between age, apoB, TG, LDL subfraction profile and BMI were determined. Associations between BMI, apoB and age were also determined in a control group of 177 healthy unaffected offspring from families diagnosed with heterozygous FH (familial hypercholesterolaemia). In all of these subjects, FH diagnosis was excluded by molecular diagnosis: none of the subjects tested positive for LDL-receptor gene mutations or apoB mutations.
Subjects from families with FCH were subdivided into two different phenotypes according to their apoB level at their recruitment visit. They were classified as 'normoapoB' when their apoB was < 75th percentile, adjusted for age and gender, or they were classified as 'hyperapoB' when their apoB level exceeded the 75th percentile [reference data obtained from NHANES III (Third National Health and Nutrition Examination Survey)] [18] . The 75th percentile of apoB was chosen as this represents a level of 1200 mg/l in adults, which is the level at which subjects were separated and analysed with regard to their cardiovascular risk in the Framingham Study [19] and the Quebec Cardiovascular Study [20] . Furthermore, it is the level at which Veerkamp et al. [6] proposed to use as a cut-off value to diagnose FCH in the absence of percentile scores for TC (total cholesterol) and TG. For 85 subjects recruited from 23 different families with FCH, 5-year follow-up data were available, and they were selected for further data analysis. By using the 75th percentile, 23 of these subjects (27 %) were classified as 'hyperapoB' at their recruitment visit, and the other 62 subjects were classified as 'normoapoB'. The effect of the 5-year follow-up on clinical and biochemical parameters was compared across these groups. The study was carried out in accordance with the declaration of Helsinki of the World Medical Association, and was approved by the Medical Ethics Committee of the Radboud University, Nijmegen Medical Centre, Nijmegen, The Netherlands. All participants provided written informed consent.
Laboratory measurements
TC and TG concentrations were determined using commercially available enzymatic reagents (BoehringerMannheim and Sera Pak respectively). HDL-C (highdensity lipoprotein cholesterol) was determined by the poly(ethylene glycol) 6000 method [21] . VLDL was isolated from whole plasma by sequential ultracentrifugation at density 1.006 g/ml for 16 h in a fixed-angle rotor in a Beckman L7-55 ultracentrifuge. LDL-C (LDL cholesterol) was calculated by subtracting VLDL-C (VLDL cholesterol) and HDL-C from total plasma cholesterol. A continuous variable K, representing the LDL subfraction profile of each individual, was determined in 1994 and 1999. A negative K value (K <− 0.1) reflects a more dense LDL subfraction profile, and a positive K value (K >− 0.1) reflects a more buoyant profile [22] . Total plasma apoB concentration was determined by immunonephelometry, as described previously [23] . Plasma glucose was determined by a commercially available glucose oxidation method (GOD-PAP, Hitachi 747; Roche Molecular Biochemicals). Plasma insulin concentrations were assessed by RIA (in-house RIA with an inter-assay coefficient of variation of 10.3 %) [24] . Insulin resistance was assessed by the HOMA (homoeostasis model assessment) index and was calculated using the formula: HOMA index = fasting serum insulin (m-units/l) × fasting plasma glucose (mmol/l)/22.5 [25] .
Statistical analysis
All values are expressed as means + − S.D. or as absolute numbers with percentages, unless stated otherwise. HOMA index, BMI, TG, VLDL-C and VLDL-TG were log-transformed to obtain normal distributions before statistical analysis. Differences between subjects with a hyperapoB phenotype and subjects with a normoapoB phenotype were tested for statistical significance by using the two-tailed Fisher exact test for dichotomous variables and a two-way ANOVA with family number as a random factor for continuous variables. A linear mixed model with repeated measurements was used to test differences in lipid and (apo)lipoprotein concentrations, BMI and HOMA index for statistical significance between both groups (normoapoB and hyperapoB) and between the points of measurement (before and after the 5-year follow-up) for each dependent variable separately. The interaction between time and group was also included in the model. The dependent variables were TC, TG, LDL-C, HDL-C, VLDL-C, VLDL-TG, apoB, BMI and HOMA index. The independent variables were time (T = 0 and Age was added as a covariate, and family number as a random factor in the linear mixed model when the effect of the independent variables was examined. Binary logistic regression was used to test for changes in incidence of dichotomous variables during follow-up with the appropriate likelihood ratio for each dependent variable assessed separately. The dependent variables were lipid-lowering medication use (yes/no), smoking (yes/no), consumption of more than one alcoholic beverage/day (yes/no) and CVD (yes/no). The independent variables were identical with those described in the linear mixed model. Univariate correlations between age, apoB and BMI as well as between intra-individual changes in plasma apoB and BMI and changes in the various apolipoproteins during follow-up were quantified by calculating Spearman's rho. For all tests, statistical significance was accepted at the 95 % confidence level (P < 0.05). Statistical analyses were performed using SPSS 12.0.1 for Windows.
RESULTS
Characteristics of young adults from families with FCH stratified by apoB concentration
Subjects with a normoapoB phenotype (n = 135) were significantly younger than the subjects with a hyperapoB phenotype (n = 59) ( Table 1) . Gender distribution was equal across both groups, with 53 % women in the normoapoB group compared with 55 % in the hyperapoB group. Clinical and biochemical characteristics for both groups are shown in Table 1 . Subjects in the hyperapoB group had a significantly higher BMI than the normoapoB group. In addition, subjects with a hyperapoB phenotype had a significantly more atherogenic lipid profile. TC, TG, LDL-C, VLDL-C and VLDL-TG concentrations as well as the VLDL-C/TG ratio were all significantly increased, whereas HDL-C concentrations were decreased. A mean K value of − 0.18 reflects the presence of sdLDL within the hyperapoB group. Although the HOMA index was higher in the hyperapoB group, this difference did not reach statistical significance.
Effect of age on plasma lipids, (apo)lipoproteins and BMI
As would be expected, in the total group of subjects recruited from families with FCH there was a significant positive correlation between age and BMI (r = 0.51, P < 0.0001). When subjects were analysed after stratification for age (< 20years), a significant association was found between age and BMI for subjects < 20 years of age (r = 0.49, P < 0.0001), but not for subjects > 20 years of age (r = 0.09, P = not significant). The significant positive association in subjects < 20 years of age, however, was not specific for subjects recruited from families with FCH. In the control group of unaffected offspring from families with FH (12-19 years of age; 46 % women; mean plasma apoB concentration, 820 + − 181 mg/l; mean plasma TG concentration, 0.84 + − 0.41 mmol/l; mean BMI, 20.1 + − 3.4 kg/m), we found a similar significant association between BMI and age (r = 0.37, P < 0.0001; Figure 1 ). When subjects with FCH were stratified according to their plasma apoB level, there was a significant association between age and BMI in both groups (normoapoB, r = 0.45, P < 0.001; hyperapoB, r = 0.47, P < 0.001; Figure 1 ).
In the population with FCH, a significant positive correlation was also present between age and apoB (r = 0.45, P < 0.001), and this association remained significant when subjects were analysed after stratification according to their plasma apoB level (normoapoB phenotype, r = 0.45, P < 0.001; hyperapoB phenotype, r = 0.47, P < 0.001; Figure 2 ). The association between age and apoB was strongest in subjects < 20 years of age (r = 0.31, P = 0.003), whereas there was no significant association between age and apoB in subjects aged > 20 years (r = 0.18, P = not significant). Again, the relationship between age and apoB in subjects < 20 years of age was not specific for subjects from families with FCH: a significant association was also found in the control group of unaffected offspring from families with FH (r = 0.21, P = 0.01; Figure 2) . In both the normoapoB and hyperapoB groups, plasma TG concentrations were associated positively with BMI (r = 0.29, P < 0.001 and r = 0.44, P < 0.001 respectively), and this was also the case for our control group of unaffected offspring from families with FH (r = 0.32, P < 0.001).
When the subgroup with a hyperapoB phenotype (n = 59) was analysed separately, 53 % of the subjects had plasma TG values < 1.5 mmol/l, which is approximately equivalent to TG values < 75th percentile adjusted for age and gender according to the population-based PROCAM (Prospective Cardiovascular Münster) study cohort [26] . The vast majority (73 %) of these subjects had large-buoyant LDL, reflected by a K value > − 0.10 (Figure 3) . On the other hand, 80 % of the subjects with TG levels > 1.5 mmol/l had sdLDL, as reflected by a K value <− 0.10. However, < 20 years of age, the presence of TG levels > 1.5 mmol/l and/or the presence of sdLDL was only observed sporadically. The presence of sdLDL in subjects with a hyperapoB phenotype correlated negatively with age (r = − 0.46, P < 0.0001). Thus plasma apoB levels were increased before plasma TG levels increased or sdLDL was present.
The early rise in plasma apoB levels in subjects < 20 years of age came with an early rise in VLDL-C concentrations (0.38 + − 0.16 compared with 0.23 + − 0.13 mmol/l for the hyperapoB and normoapoB groups respectively; P < 0.05) and an elevated VLDL-C/TG ratio (0.34 + − 0.07 compared with 0.28 + − 0.08 for the hyperapoB and normoapoB groups respectively; P < 0.05) as well. Older hyperapoB subjects (> 20 years of age) exhibited even higher VLDL-C concentrations than younger (< 20 years of age) hyperapoB subjects (0.74 + − 0.47 compared with 0.38 + − 0.16 mmol/l respectively). This is a reflection of the presence of an increased number of more VLDL particles, rather than a change in composition of these particles as they have higher apoB levels than younger hyperapoB subjects (1175 + − 146 compared with 1018 + − 109 mg/l respectively; P < 0.01), but not a higher VLDL-C/TG ratio (0.36 + − 0.08 compared with 0.34 + − 0.07 respectively; P = not significant).
Changes in lifestyle variables after the 5-year follow-up
At the time of their recruitment, mean age was 19.4 + − 3.7 years in the normoapoB group and 20.9 + − 3.8 years in the hyperapoB group (P = 0.09). None of the subjects used lipid-lowering medication. Seven out of 23 subjects (30 %) smoked cigarettes in the hyperapoB group compared with 23 out of 62 (37 %) in the normoapoB group (P = 0.48). The number of subjects drinking more than one alcoholic beverage/day (two in the normoapoB group and one in the hyperapoB group) was not significantly different (P = 0.29). None of the participants had any past or present history of CVD at the time of their recruitment.
After a 5-year follow-up, only one subject in both groups used lipid-lowering medication. The percentage of subjects consuming more than one alcoholic beverage/ day was significantly higher than at the recruitment visit (P < 0.001), but no significant differences across the groups were observed. The percentage of subjects smoking cigarettes did not change significantly compared with recruitment (P = 0.87). After the 5-year followup, none of the subjects had any past or present CVD. Table 2 shows the baseline BMI, lipid and (apo)-lipoprotein concentrations and HOMA indices for the 23 subjects with a plasma level of apoB > 75th percentile adjusted for age and gender, and for the 62 subjects with a plasma level of apoB < 75th percentile. In these groups, the same (significant) differences in baseline BMI, HOMA index, K value and lipid and (apo)lipoprotein concentrations between the two groups were observed, as presented above for the whole group of subjects (n = 194). A significant effect on BMI after 5-year follow-up was found in the linear mixed model; however, this effect was not group-dependent (i.e. there was no timeto-group interaction in the model). In both groups, BMI increased significantly after the 5-year follow-up (P < 0.001 and P = 0.002 respectively). This increase in Table 2 BMI could be attributed to a mean weight gain of 5.1 kg (from 64.8 to 70.9 kg) in the normoapoB group, and to a weight gain of 4.5 kg (from 79.5 to 84 kg) in the hyperapoB group. The difference in weight between the two groups was substantial both at the beginning and at the end of the 5-year follow-up period. In both groups, apoB, TC and LDL-C concentrations were increased after the 5-year follow-up, but these increases only reached statistical significance in the normoapoB group (P = 0.02, P < 0.001 and P = 0.002 respectively). For apoB, LDL-C and TC, however, time-to-group interaction was not significant (i.e. the increase in apoB, TC and LDL-C concentrations in the normoapoB group was not significantly different from the increase in the hyperapoB group). The higher plasma concentrations of TG, VLDL-C and VLDL-TG, as well as the higher VLDL-C/TG-ratio and the higher HOMA index, in the hyperapoB group at the recruitment visit remained higher after the 5-year follow-up. In both the normoapoB and hyperapoB groups, only small changes in mean values were recorded, which only reached significance in the larger normoapoB group. As a result, there was no significant effect of the 5-year followup on these parameters using the linear mixed model nor was there a significant time-to-group interaction for any of these parameters. As the K value was determined in 1994 and 1999 only and not in 2004, the number of hyperapoB subjects with 5-year follow-up data on the K value (n = 10) was too small to draw any firm conclusions regarding the effect of follow-up on the occurrence of sdLDL in this group. In the normoapoB subjects (n = 26), however, we observed a significant decrease in K value with increasing age (P < 0.001). 
Changes in plasma lipid and (apo)lipoprotein concentrations, and BMI after the 5-year follow-up
Factors affecting intra-individual changes in BMI and apoB after the 5-year follow-up
Univariate regression analysis (n = 85) revealed that intraindividual changes in apoB concentration after follow-up were associated not only with changes in TC, LDL-C and VLDL-C, but also with changes in BMI and VLDL-TG and TG concentrations (Table 3) . Furthermore, intra-individual changes in BMI were associated with changes in apoB, VLDL-C, VLDL-TG, HDL-C and TG concentrations (Table 3) .
DISCUSSION
To the best of our knowledge, the present study is the first to examine the effect of age and body weight on phenotype expression of FCH in a large cohort of children and young adults recruited from families with FCH. We have shown that an elevated apoB concentration is the first expression of FCH in children and young adults. Furthermore, our data support the hypothesis that age-related factors, such as expansion of adipose tissue mass, contribute to the phenotype expression in patients with FCH. We found that in FCH plasma apoB and TGs, BMI and LDL-particle size were all associated with age. These associations were independent of the apoB phenotype (normoapoB or hyperapoB). Furthermore, the associations between age, BMI and apoB were not specific for subjects recruited from families with FCH, as similar associations were also present in a control group of unaffected offspring from families with FH.
The majority of subjects with an elevated apoB but younger than 20 years of age had no elevated plasma TG levels or sdLDL, although these traits are frequently observed in adult patients with FCH. This suggests that increased secretion of apoB may be the primary abnormality in FCH. On the other hand, the positive trends between plasma TG concentration and age, between age and BMI, and between BMI and plasma TG concentration suggest that increasing adipose tissue mass is a major driver of plasma TGs and that this is a secondary trend affecting the expression of FCH. This is in concordance with our finding that the 59 subjects with a hyperapoB phenotype in the present study not only had a higher plasma apoB concentration, but they also had a higher BMI as well as a more atherogenic lipid profile than their 135 normoapoB relatives. The combination of a higher BMI and higher plasma TG levels points to a role of adipose tissue in the pathogenesis of their elevated apoB levels by virtue of an increased hepatic NEFA flux.
The results from the 5-year follow-up were in line with these findings. BMI and apoB increased in both the normoapoB and hyperapoB groups (although not significantly in the latter). Furthermore, the intra-individual increase in BMI after the 5-year follow-up appeared to be significantly associated with intra-individual changes in plasma apoB concentration. Of importance, the influence of changes in BMI on levels of apoB was not confined to a specific phenotype. Taken together, these findings favour the hypothesis that increased hepatic apoB secretion in subjects with FCH might be augmented by post-maturational changes in adipose tissue mass.
The observed lack of change in mean plasma concentrations of VLDL-C, VLDL-TG, TG and apoB, and HOMA index after the 5-year follow-up might be related to the relatively small increases in the mean value of BMI. Datillo et al. [27] have shown in a meta-analysis that every kg of weight reduction is associated with a change in TG of 0.015 mmol/l. Since the mean weight change in our present study was only 4.8 kg, we would not have expected more than a 0.072 mmol/l increase in plasma levels of TG. Our actual data are concordant with this relationship. The same may well be true for VLDL-C, VLDL-TG and HOMA index values. Alternatively, in a recent study, Noakes and Clifton [28] identified dietary composition and physical exercise as significant mediators of the relationship between weight gain and plasma lipid and lipoprotein concentrations. Since these parameters were not assessed in the present study, they could have acted as confounders. Beyond these factors, it is worth emphasizing that no simple relationship between BMI and apoB expression should be anticipated. To the extent that adipose tissue mass influences the level of plasma apoB, it does so based on its effect on hepatic NEFA flux. Lower-body adipose tissue is associated with low adipocyte transmembrane NEFA fluxes and, therefore, low hepatic NEFA fluxes. By contrast, upperbody adipose tissue is associated with higher adipocyte transmembrane NEFA fluxes and higher hepatic NEFA fluxes. Upper-body adipose tissue mass does not expand until the lower-body adipose tissue reservoirs are filled [29] . This explains why there is a closer relationship between waist-to-hip ratio and plasma apoB, insulin resistance and the risk of vascular disease than between BMI and these indices [30] .
Our present study has limitations. Almost all of our subjects were post-adolescent and follow-up data were available for only a subset and, in these, only over a relatively short period of time. Nevertheless, we consider these data to be of interest. First, very limited data are available on the phenotypic expression of FCH in young subjects from affected families, and the present study represents the largest data set available. Secondly, the results confirm our previous studies in adults that plasma apoB is the most reliable marker in affected individuals [16] . Thirdly, the results indicate that FCH is expressed relatively early in life. At an average age of 21.9 years, the absolute apoB concentration in the 59 subjects in the hyperapoB group was 1119 mg/l, a value of apoB that is only slightly less than the level (1200 mg/l) used in adults to diagnose FCH [6] . Although TG, VLDL-C and VLDL-TG concentrations, as well as the HOMA index, were also elevated in the hyperapoB subjects, the mean values for these parameters were much lower than the corresponding values found in adult patients with FCH [16] . These findings are in line with an earlier (albeit crosssectional) study demonstrating a high incidence (86 %) of elevated plasma apoB in children and young adults from families with FCH, whereas the incidence of the hypertriglyceridaemia/hyperapoB phenotype was only 35 % [31] .
Taken together, the available data suggest there may be two processes augmenting the elevated plasma apoB levels in FCH. The first would be a primary defect responsible for the high apoB levels early in life, possibly related to sterol balance within the liver [32] . Multiple lines of evidence have established that regulation of hepatic sterol content is a fundamental metabolic role for apoB secretion and that the rate of hepatic apoB secretion is directly related to the mass of cholesterol ester on the endoplasmic reticulum. Hepatic NEFA flux is only one of several determinants of cholesterol ester mass. It seems possible therefore that the final phenotypic expression of FCH is the interplay between a primary genetically determined abnormality in hepatic sterol balance and the superimposed secondary effects of increased NEFA flux resulting from the expansion of upper-body adipose tissue mass.
Conclusions
In the present study, we have found indirect evidence of a presumably genetically determined increase in apoB production rate occurring early in life in offspring of families with FCH. Furthermore, we have shown that agingrelated factors, such as post-maturation increases in adipose tissue mass, contributed to an aggravation and/ or modulation of this genetically determined apoB overproduction.
